CClinicalTrials.gg
Sign In
WithdrawnNCT02790528STAVAUpdated Jun 15, 2017

Statin Therapy In Patients With Vasospastic Angina

A Phase 4 interventional study of Atorvastatin and Placebo in Angina Pectoris, Variant and Statins, HMG-CoA, sponsored by Seung-Jung Park. Withdrawn at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2017-06-15.

Sponsored by Seung-Jung Park · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Funding issue
Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate whether statin is effective in the treatment of vasospastic angina.

02

Conditions studied

  • Angina Pectoris, Variant
  • Statins, HMG-CoA

Keywords

  • statin
  • vasospastic angina
03

In context

Angina Pectoris

519 studies on the registry are indexed under Angina Pectoris; 82 are open to participants now.

Browse Angina Pectoris studies →

Lead sponsor

Seung-Jung Park is the lead sponsor of 82 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 19 and more
  • Vasospastic angina
  • LDL less than 160mg/dl
  • Written consent

Exclusion criteria

Exclusion Criteria:

  • Coronary artery stenosis more than 50% or ischemic coronary disease
  • History of percutaneous coronary intervention
  • Cerebrovascular diseases or peripheral
  • Dyslipidemia required statin therapy
  • Heart failure, arrhythmogenic right ventricular dysplasia, hypertrophic cardiomyopathy, akinesia or aneurysm on left ventricular wall, anomaly of coronary artery
  • NYHA III and IV
  • Arrhythmia
  • Primary cardiac electrical diseases
  • Cardiac pacemaker or implantable defibrillator
  • Pregnancy or breast feeding
  • Life expectancy less than 2 years
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Atorvastatin

    20mg QD

    Drug: Atorvastatin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugAtorvastatin

    20mg QD

  • DrugPlacebo

    Placebo drug will be administered.

06

What researchers measure

Primary outcomes

  1. The Composite Event of all-cause death, myocardial infarction, angina-related hospitalization

    The number of events with the first occurrence of a composite event(all-cause death, myocardial infarction, angina-related hospitalization)

    Time frame: 3 years

Secondary outcomes

  1. all-cause death

    Time frame: 3 years

  2. cardiac death

    Time frame: 3 years

  3. cardiac arrest

    Time frame: 3 years

  4. myocardial infarction

    Time frame: 3 years

  5. angina-related hospitalization

    Time frame: 3 years

  6. Composite event of death or myocardial infarction

    Time frame: 3 years

  7. Composite event of cardiac death or myocardial infarction

    Time frame: 3 years

  8. statin-related complications

    event rate of statin-related complications

    Time frame: 3 years

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Songpa-gu 138-736, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No — This is not a publicly funded trial.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02790528
Lead sponsor
Seung-Jung Park
Collaborators
CardioVascular Research Foundation, Korea
Responsible party
Seung-Jung Park (professor of medicine, Asan Medical Center) — Sponsor-investigator
First posted
Jun 6, 2016
Start date
Jul 2017 (estimated)
Primary completion
Jun 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Jun 15, 2017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Angina Pectoris→

Other studies from this sponsor

Seung-Jung Park

Start the discussion